544-64-9
中文名稱(chēng)
肉豆蔻油酸
英文名稱(chēng)
MYRISTOLEIC ACID
CAS
544-64-9
分子式
C14H26O2
分子量
226.36
MOL 文件
544-64-9.mol
更新日期
2024/11/14 17:46:45
544-64-9 結(jié)構(gòu)式
基本信息
中文別名
肉豆蔻油酸肉豆蔻腦酸
9-十四烯酸
順9-肉豆蔻烯酸
十四碳烯酸(順-9)
(Z)-9-十四烯酸
順-9-十四碳烯酸/肉豆蔻油酸
英文別名
MYRISTOLEIC ACIDMyristolenic acid
C14:1 (CIS-9) ACID
MYRISTOLEIC ACID 99%
9-tetradecenoic acid
(z)-9-tetradecenoicaci
(Z)-9-Tetradecenoicacid
9-cis-Tetradecenoic acid
CIS-9-TETRADECENOIC ACID
(Z)-tetradec-9-enoic acid
所屬類(lèi)別
分析化學(xué)：脂肪酸、脂肪酸甲酯物理化學(xué)性質(zhì)
熔點(diǎn)−4.5-−4 °C(lit.)
沸點(diǎn)144 °C0.6 mm Hg(lit.)
密度0.9 g/mL at 25 °C(lit.)
折射率n20/D 1.4562(lit.)
閃點(diǎn)62 °C
儲(chǔ)存條件−20°C
溶解度苯（微量）、氯仿（微量）、甲醇（微量）
酸度系數(shù)(pKa)4.78±0.10(Predicted)
形態(tài)液體
顏色無(wú)色
LogP5.383 (est)
EPA化學(xué)物質(zhì)信息9-Tetradecenoic acid, (9Z)- (544-64-9)
安全數(shù)據(jù)
警示詞警告
危險(xiǎn)性描述H315-H319-H335
危險(xiǎn)品標(biāo)志Xi
危險(xiǎn)類(lèi)別碼36/37/38
安全說(shuō)明26-36
危險(xiǎn)品運(yùn)輸編號(hào)NA 1993 / PGIII
WGK Germany3
肉豆蔻油酸價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱(chēng) | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/11/08 | HY-113332 | 肉豆蔻油酸 Myristoleic acid | 544-64-9 | 100mg | 1800元 |
| 2022/04/29 | HY-113332 | 肉豆蔻油酸 Myristoleic acid | 544-64-9 | 50mg | 4000元 |
常見(jiàn)問(wèn)題列表
生物活性
Myristoleic acid 是 Serenoa repens 提取物中的一種細(xì)胞毒性成分，可誘導(dǎo)人前列腺細(xì)胞的凋亡和壞死。體外研究
Myristoleic acid induces both apoptosis (100 μg/mL, 89.5%) and necrosis (100 μg/mL, 81.8%) in LNCaP cells.
Myristoleic acid inhibited RANKL-induced osteoclast formation in vitro, especially, at later stages of differentiation.
Cell Proliferation Assay
| Cell Line: | Human prostatic carcinoma LNCaP cells. |
| Concentration: | 0, 50, 100, 150, 200, 250 μg/mL. |
| Incubation Time: | 24 h. |
| Result: | When LNCaP cells were treated with 130 μg/mL extract or 100 μg/mL myristoleic acid for 24 hr, the proportion of apoptotic cells was 16.5 and 8.8%, and that of necrotic one was 46.8 and 81.8%, respectively. |
體內(nèi)研究
Myristoleic acid (2 mg/kg, IP every 24 h for 4 days) prevents RANKL-induced bone loss and osteoclast formation in mice.
| Animal Model: |
C57BL/6 mice at 5 weeks.
|
| Dosage: | 0.2, 2 mg/kg |
| Administration: | IP every 24 h for 4 days. |
| Result: | Co-administration of myristoleic acid suppressed generation of TRAP-positive osteoclasts induced by sRANKL and attenuated the increases in osteoclastic indices of Oc.S/BS, N.Oc/B. Pm and ES/BS in a dose-dependent manner. |